Earnings ·
Vir Biotechnology reported second quarter 2026 financial results on August 5, 2026
VIRVir Biotechnology, Inc.
Vir Biotechnology reported second quarter 2026 financial results on August 5, 2026. The company recognized $238.9 million in license and collaboration revenue, primarily from a $240.0 million upfront payment received from Astellas. Net income was $80.1 million, or $0.48 per share basic, compared to a net loss of $111.0 million in the prior year period. Cash, cash equivalents, and investments totaled approximately $1.01 billion at quarter-end. The company closed its global strategic collaboration with Astellas for VIR-5500 and initiated additional Phase 1 dose-expansion cohorts for this prostate cancer candidate. Topline data from the Phase 3 ECLIPSE 1 trial for chronic hepatitis delta is expected in Q4 2026, while ECLIPSE 2 and 3 data are expected in Q1 2027. Vir Biotechnology operates as a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases and cancer.